RhumbLine Advisers
KPTI icon

RhumbLine Advisers’s Karyopharm Therapeutics KPTI Stock Holding History

RhumbLine Advisers’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,095
Closed -$14.3K – 4266
2024
Q2 		$14.3K Sell
1,095
-8,507
-89% -$141K ﹤0.01% 3924
2024
Q1 		$217K Buy
9,602
+395
+4% +$6.93K ﹤0.01% 3139
2023
Q4 		$119K Sell
9,207
-3
-0% -$40 ﹤0.01% 3392
2023
Q3 		$185K Buy
9,210
+238
+3% +$5.34K ﹤0.01% 3200
2023
Q2 		$241K Buy
8,972
+2,019
+29% +$87K ﹤0.01% 3141
2023
Q1 		$406K Buy
6,953
+370
+6% +$18.3K ﹤0.01% 2511
2022
Q4 		$336K Sell
6,583
-66
-1% -$4.58K ﹤0.01% 2633
2022
Q3 		$545K Buy
6,649
+554
+9% +$41.4K ﹤0.01% 2460
2022
Q2 		$412K Buy
6,095
+820
+16% +$75.2K ﹤0.01% 2594
2022
Q1 		$583K Sell
5,275
-1,039
-16% -$129K ﹤0.01% 2353
2021
Q4 		$609K Sell
6,314
-99
-2% -$9.87K ﹤0.01% 2427
2021
Q3 		$560K Sell
6,413
-1,966
-23% -$204K ﹤0.01% 2496
2021
Q2 		$1.3M Buy
8,379
+317
+4% +$46K ﹤0.01% 2133
2021
Q1 		$1.27M Sell
8,062
-252
-3% -$53.1K ﹤0.01% 2096
2020
Q4 		$1.93M Buy
8,314
+200
+2% +$46.3K ﹤0.01% 1861
2020
Q3 		$1.78M Sell
8,114
-1,243
-13% -$304K ﹤0.01% 1743
2020
Q2 		$2.66M Buy
9,357
+939
+11% +$278K ﹤0.01% 1572
2020
Q1 		$2.43M Buy
8,418
+170
+2% +$46.9K 0.01% 1442
2019
Q4 		$2.37M Buy
8,248
+521
+7% +$113K ﹤0.01% 1705
2019
Q3 		$1.11M Buy
7,727
+29
+0.4% +$3.93K ﹤0.01% 1991
2019
Q2 		$692K Sell
7,698
-1,139
-13% -$91.5K ﹤0.01% 2227
2019
Q1 		$774K Buy
8,837
+2,582
+41% +$286K ﹤0.01% 2145
2018
Q4 		$879K Buy
6,255
+3,411
+120% +$575K ﹤0.01% 2071
2018
Q3 		$726K Sell
2,844
-178
-6% -$49.2K ﹤0.01% 2133
2018
Q2 		$770K Buy
3,022
+785
+35% +$194K ﹤0.01% 2128
2018
Q1 		$450K Buy
2,237
+65
+3% +$13K ﹤0.01% 2252
2017
Q4 		$313K Sell
2,172
-2,842
-57% -$456K ﹤0.01% 2450
2017
Q3 		$826K Buy
5,014
+27
+0.5% +$3.87K ﹤0.01% 2069
2017
Q2 		$677K Buy
4,987
+401
+9% +$59.4K ﹤0.01% 2157
2017
Q1 		$883K Buy
4,586
+266
+6% +$42.7K ﹤0.01% 1991
2016
Q4 		$609K Sell
4,320
-1,119
-21% -$151K ﹤0.01% 2120
2016
Q3 		$794K Buy
5,439
+1,142
+27% +$137K ﹤0.01% 1949
2016
Q2 		$433K Buy
4,297
+2,808
+189% +$365K ﹤0.01% 2283
2016
Q1 		$199K Buy
1,489
+6
+0.4% +$662 ﹤0.01% 2734
2015
Q4 		$295K Buy
1,483
+100
+7% +$21.7K ﹤0.01% 2592
2015
Q3 		$218K Buy
1,383
+81
+6% +$21.7K ﹤0.01% 2743
2015
Q2 		$531K Buy
1,302
+406
+45% +$175K ﹤0.01% 2284
2015
Q1 		$411K Buy
896
+192
+27% +$82.8K ﹤0.01% 2419
2014
Q4 		$395K Buy
704
+21
+3% +$11.9K ﹤0.01% 2420
2014
Q3 		$358K Sell
683
-18
-3% -$10.2K ﹤0.01% 2418
2014
Q2 		$490K Buy
+701
New +$326K ﹤0.01% 2283

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

RhumbLine Advisers's KPTI Position: Q3 2024 in Review

RhumbLine Advisers sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,095 shares — an estimated $14.3K sold.

RhumbLine Advisers first reported a position in KPTI in Q2 2014 and held it in 41 quarters. The position peaked at $2.66M in Q2 2020. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • RhumbLine Advisers reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 1,095 Karyopharm Therapeutics shares in Q3 2024, an estimated $14.3K.
  • RhumbLine Advisers first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 41 quarters.
  • RhumbLine Advisers's Karyopharm Therapeutics position peaked at $2.66M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.